NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free LEXX Stock Alerts $3.56 +0.13 (+3.79%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$3.34▼$3.5650-Day Range$1.99▼$6.2552-Week Range$0.65▼$6.85Volume102,771 shsAverage Volume395,761 shsMarket Capitalization$45.89 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lexaria Bioscience alerts: Email Address Lexaria Bioscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside247.8% Upside$12.00 Price TargetShort InterestHealthy3.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector432nd out of 905 stocksPharmaceutical Preparations Industry195th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingLexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexaria Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.70% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently decreased by 11.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEXX. Previous Next 2.5 News and Social Media Coverage News SentimentLexaria Bioscience has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lexaria Bioscience this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LEXX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of Lexaria Bioscience is held by insiders.Percentage Held by InstitutionsOnly 13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.46) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 10.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexaria Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Lexaria Bioscience Stock (NASDAQ:LEXX)Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Read More LEXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEXX Stock News HeadlinesMay 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)May 8, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot StudyMay 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 7, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 DrugsMay 2, 2024 | americanbankingnews.comFY2024 Earnings Forecast for Lexaria Bioscience Corp. Issued By Zacks Small Cap (NASDAQ:LEXX)May 1, 2024 | americanbankingnews.comZacks Small Cap Weighs in on Lexaria Bioscience Corp.'s Q3 2024 Earnings (NASDAQ:LEXX)May 1, 2024 | americanbankingnews.comHead-To-Head Comparison: Zoetis (NYSE:ZTS) versus Lexaria Bioscience (NASDAQ:LEXX)April 30, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and IssuanceMay 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. April 17, 2024 | msn.comLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversApril 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyApril 5, 2024 | morningstar.comLexaria Bioscience Corp LEXXMarch 19, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension TrialMarch 18, 2024 | proactiveinvestors.comLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugMarch 15, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOMarch 14, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial OfficerMarch 7, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot StudyMarch 5, 2024 | msn.comLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesMarch 4, 2024 | finanznachrichten.deLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal StudyMarch 4, 2024 | finance.yahoo.com7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal StudyMarch 1, 2024 | msn.comLexaria slips despite FDA nod to test blood pressure drugFebruary 18, 2024 | finance.yahoo.comThis Lexaria Bioscience Insider Increased Their Holding By 23% Last YearFebruary 16, 2024 | finance.yahoo.comLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finance.yahoo.comLexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 13, 2024 | theglobeandmail.comLexaria Bioscience’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 DrugJanuary 30, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) To Hit High Ground in Q2/Q3 2024 with Animal, Human GLP-1 StudiesSee More Headlines Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/09/2024Today5/08/2024Next Earnings (Estimated)7/12/2024Fiscal Year End8/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEXX CUSIPN/A CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+244.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,660,000.00 Net MarginsN/A Pretax Margin-1,417.36% Return on Equity-133.97% Return on Assets-118.89% Debt Debt-to-Equity RatioN/A Current Ratio66.29 Quick Ratio66.29 Sales & Book Value Annual Sales$230,000.00 Price / Sales195.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book10.55Miscellaneous Outstanding Shares12,890,000Free Float11,905,000Market Cap$44.86 million OptionableNot Optionable Beta0.99 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Christopher A. Bunka (Age 62)Chairman & CEO Comp: $291.19kMr. John M. Docherty M.Sc. (Age 55)President & Director Comp: $290.46kMr. Nelson D. Cabatuan CPA (Age 45)Chief Financial Officer Kristin HamiltonDirector of OperationsVanessa CarleHead of LegalDr. Philip N. Ainslie Ph.D.Advisor & ConsultantMore ExecutivesKey CompetitorsNextCureNASDAQ:NXTCUnicycive TherapeuticsNASDAQ:UNCYCara TherapeuticsNASDAQ:CARASensei BiotherapeuticsNASDAQ:SNSENabriva TherapeuticsNASDAQ:NBRVView All CompetitorsInstitutional OwnershipWelch Group LLCBought 24,000 shares on 4/9/2024Ownership: 0.194%Invenomic Capital Management LPSold 32,351 shares on 2/14/2024Ownership: 7.011%Cowen AND Company LLCBought 256,327 shares on 2/8/2024Ownership: 2.455%View All Institutional Transactions LEXX Stock Analysis - Frequently Asked Questions Should I buy or sell Lexaria Bioscience stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexaria Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LEXX shares. View LEXX analyst ratings or view top-rated stocks. What is Lexaria Bioscience's stock price target for 2024? 1 brokers have issued 1-year price targets for Lexaria Bioscience's stock. Their LEXX share price targets range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 247.8% from the stock's current price. View analysts price targets for LEXX or view top-rated stocks among Wall Street analysts. How have LEXX shares performed in 2024? Lexaria Bioscience's stock was trading at $1.25 at the beginning of the year. Since then, LEXX stock has increased by 176.0% and is now trading at $3.45. View the best growth stocks for 2024 here. Are investors shorting Lexaria Bioscience? Lexaria Bioscience saw a decrease in short interest in March. As of March 31st, there was short interest totaling 490,400 shares, a decrease of 35.0% from the March 15th total of 754,500 shares. Based on an average trading volume of 465,300 shares, the short-interest ratio is currently 1.1 days. Approximately 4.3% of the company's stock are short sold. View Lexaria Bioscience's Short Interest. When is Lexaria Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our LEXX earnings forecast. How were Lexaria Bioscience's earnings last quarter? Lexaria Bioscience Corp. (NASDAQ:LEXX) issued its quarterly earnings data on Tuesday, April, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.15 million for the quarter. Who are Lexaria Bioscience's major shareholders? Lexaria Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Welch Group LLC (0.19%). View institutional ownership trends. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LEXX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
